%0 Conference Paper
%A Stark, Melina
%A Kuhn, Elizabeth
%A Wagner, Michael
%A Boecker, Henning
%A Brosseron, Frederic
%A Buerger, Katharina
%A Daamen, Marcel
%A Laske, Christoph
%A Perneczky, Robert
%A Peters, Oliver
%A Priller, Josef
%A Schmid, Matthias
%A Schneider, Anja
%A Spottke, Annika
%A Teipel, Stefan J
%A Wiltfang, Jens
%A Düzel, Emrah
%A Jessen, Frank
%A Kleineidam, Luca
%T Subjective Cognitive Decline and Minor Neuropsychological Deficits: Importance for Risk Stratification and Trial Recruitment in Early Alzheimer´s Disease
%J Alzheimer's and dementia
%V 21
%N Suppl 3
%@ 1552-5260
%M DZNE-2025-01475
%P e102815
%D 2025
%X The recruitment of participants with a high risk of decline is crucial for the success of clinical trials in the earliest phases of Alzheimer´s Disease (AD), where treatment benefits could be the largest. Subjective cognitive decline (SCD) and minor neuropsychological deficits (MNPD) are associated with an increased risk of cognitive decline, making them promising predictors for this risk stratification. However, the prognostic value of their interplay is understudied.We pooled and analyzed data from cognitively unimpaired participants from the Alzheimer´s Disease Neuroimaging Initiative (N = 599), DZNE Longitudinal Cognitive Impairment and Dementia study (N = 618), and National Alzheimer's Coordinating Center (N = 11,975). SCD was measured using questionnaires or anamnestic data. MNPD was defined as a median neuropsychological test performance of z≤-0.5. We assessed the association of MNPD and SCD with the conversion to mild cognitive impairment (MCI) and dementia (cox regression) and baseline amyloid and tau positivity - measured by PET/CSF (logistic regression). We adjusted these models for the study cohorts and demographic covariates. Using power analyses, we calculated the sample sizes necessary to detect a 30
%B Alzheimer’s Association International Conference
%C 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2 27 Jul 2025 - 31 Jul 2025
M2 Toronto, Canada
%K Humans
%K Male
%K Female
%K Aged
%K Cognitive Dysfunction: diagnosis
%K Cognitive Dysfunction: diagnostic imaging
%K Cognitive Dysfunction: cerebrospinal fluid
%K Cognitive Dysfunction: psychology
%K Neuropsychological Tests
%K Alzheimer Disease: diagnostic imaging
%K Alzheimer Disease: diagnosis
%K Alzheimer Disease: cerebrospinal fluid
%K Alzheimer Disease: psychology
%K tau Proteins: cerebrospinal fluid
%K Disease Progression
%K Longitudinal Studies
%K Aged, 80 and over
%K Positron-Emission Tomography
%K Amyloid beta-Peptides: cerebrospinal fluid
%K Biomarkers: cerebrospinal fluid
%K tau Proteins (NLM Chemicals)
%K Amyloid beta-Peptides (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%F PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
%9 AbstractJournal Article
%$ pmid:41447391
%2 pmc:PMC12740029
%R 10.1002/alz70857_102815
%U https://pub.dzne.de/record/283068